Cross-species-specific psmaxcd3 bispecific single chain antibody
NZ591087A
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
WO2009133103A1
Inhibitors of gm-csf and il-17 for therapy
BRPI0809595A2
"Polypeptide, nucleic acid sequence, vector, host, process for production of a polypeptide, pharmaceutical composition, use of a polypeptide, method for the prevention, treatment or improvement of a disease"
CN102961747A
Treatment of metastatic breast cancer
US2009304716A1
Treatment of metastatic breast cancer
NZ569144A
Pharmaceutical antibody compositions with resistance to soluble CEA - comprising IgG1antibodies that bind to CEA
ZA200805400B
Pharmaceutical compositions with resistance to soluble CEA
MX2008008046A
Epha2 bite molecules and uses thereof.
WO2007068488A1
Domain-grafted antibodies
CN101331151A
Means and methods for the treatment of tumorous diseases
WO2007042261A2
Compositions comprising cross-species-specific antibodies and uses thereof
AU2006215823A1
Use of activated polymers for separation of protein and polypeptide multimers
CA2555503A1
Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto
EP2186527A1
Compositions comprising polypeptides
BRPI0415457A
cytotoxically active cd3 specific binding construct, its production process, composition comprising the same, nucleic acid sequence, vector, host, its uses in the preparation of a pharmaceutical composition and kit comprising the same
EP1524275A2
Deimmunized binding molecules to CD3
CN1812999A
Pharmaceutical composition comprising a bispecific antibody specific for EpCAM
AU2004242846A1
Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
